Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · President and CEO | November 27, 2018 | November 30, 2018 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 75,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 75,000 · Balance 75,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
GILEAD SCIENCES, INC.
Report date November 27, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,574,306 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Exercise / conversion · Acquired 280,000 · Balance 1,574,306 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.60 · Expires 2019-01-21 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-27 · Exercise / conversion · Disposed 280,000 · Balance 0 F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2015 Filed Jul 9, 2015 20:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 25,315 | $115.74 | $2,930,026.45 |
DisclosureSEC source: 0001179110-15-011071 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,408 F5 · price: Sale prices reported for the transactions reported here range from $115.24 to $116.20. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 07, 2015 Filed Jul 9, 2015 20:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 22,720 | $114.76 | $2,607,388.10 |
DisclosureSEC source: 0001179110-15-011071 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,054,723 F4 · price: Sale prices reported for the transactions reported here range from $114.23 to $115.22. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 07, 2015 Filed Jul 9, 2015 20:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 51,665 | $113.65 | $5,871,747.92 |
DisclosureSEC source: 0001179110-15-011071 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,443 F3 · price: Sale prices reported for the transactions reported here range from $113.19 to $114.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 07, 2015 Filed Jul 9, 2015 20:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $14.50 | $1,450,250.00 |
DisclosureSEC source: 0001179110-15-011071 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2015 Filed Jun 10, 2015 17:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-15-009467 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 100,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| June 08, 2015 Filed Jun 10, 2015 17:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,250 | $114.65 | $487,280.35 |
DisclosureSEC source: 0001179110-15-009467 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 F4 · price: Sale prices reported for the transactions reported here range from $114.60 to $114.75. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 08, 2015 Filed Jun 10, 2015 17:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 95,750 | $114.03 | $10,918,133.13 |
DisclosureSEC source: 0001179110-15-009467 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,358 F3 · price: Sale prices reported for the transactions reported here range from $113.56 to $114.56. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 08, 2015 Filed Jun 10, 2015 17:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $14.50 | $1,450,250.00 |
DisclosureSEC source: 0001179110-15-009467 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2015 Filed May 12, 2015 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-15-007574 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 100,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 07, 2015 Filed May 12, 2015 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,951 | $101.94 | $1,626,028.99 |
DisclosureSEC source: 0001179110-15-007574 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 F5 · price: Sale prices reported for the transactions reported here range from $101.73 to $102.26. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 07, 2015 Filed May 12, 2015 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 57,310 | $101.03 | $5,789,828.72 |
DisclosureSEC source: 0001179110-15-007574 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,045,059 F4 · price: Sale prices reported for the transactions reported here range from $100.72 to $101.72. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 07, 2015 Filed May 12, 2015 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 26,739 | $100.39 | $2,684,304.14 |
DisclosureSEC source: 0001179110-15-007574 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,369 F3 · price: Sale prices reported for the transactions reported here range from $99.71 to $100.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 07, 2015 Filed May 12, 2015 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $14.50 | $1,450,250.00 |
DisclosureSEC source: 0001179110-15-007574 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2015 Filed Feb 19, 2015 23:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 106,970 | $103.84 | $11,107,764.80 |
DisclosureSEC source: 0001179110-15-002982 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 Read SEC document |
| February 17, 2015 Filed Feb 19, 2015 23:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 136,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-002982 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,078 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on January 26, 2012. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 17, 2015 Filed Feb 19, 2015 23:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 25,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-002982 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 999,410 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of performance share awards made to the Reporting Person on February 1, 2013, and February 1, 2014. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2015 and December 31, 2016, respectively. Read SEC document |
| February 13, 2015 Filed Feb 19, 2015 23:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 248 | $85.61 | $21,231.78 |
DisclosureSEC source: 0001179110-15-002982 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,296 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 01, 2015 Filed Feb 4, 2015 02:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 70,290 | $0.00 Strike: $104.83 | $0.00 |
DisclosureSEC source: 0001179110-15-001669 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,290 Underlying: Common Stock · 70,290 shares Expires 2025-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 08, 2014 Filed Dec 10, 2014 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 146,823 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001179110-14-017907 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 146,823 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| December 08, 2014 Filed Dec 10, 2014 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 114,315 | $106.55 | $12,179,771.70 |
DisclosureSEC source: 0001179110-14-017907 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,048 F4 · price: Sale prices reported for the transactions reported here range from $106.00 to $106.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 08, 2014 Filed Dec 10, 2014 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 32,508 | $105.25 | $3,421,349.97 |
DisclosureSEC source: 0001179110-14-017907 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088,363 F3 · price: Sale prices reported for the transactions reported here range from $105.00 to $105.97. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 08, 2014 Filed Dec 10, 2014 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 146,823 | $8.01 | $1,175,318.12 |
DisclosureSEC source: 0001179110-14-017907 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2014 Filed Nov 12, 2014 17:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 146,895 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001179110-14-016399 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,823 Underlying: Common Stock · 146,895 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 07, 2014 Filed Nov 12, 2014 17:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,346 | $108.77 | $799,028.09 |
DisclosureSEC source: 0001179110-14-016399 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,048 F5 · price: Sale prices reported for the transactions reported here range from $108.41 to $108.95. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 07, 2014 Filed Nov 12, 2014 17:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 73,187 | $107.71 | $7,882,642.43 |
DisclosureSEC source: 0001179110-14-016399 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 981,394 F4 · price: Sale prices reported for the transactions reported here range from $107.345 to $108.34. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 07, 2014 Filed Nov 12, 2014 17:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 66,362 | $106.85 | $7,091,065.06 |
DisclosureSEC source: 0001179110-14-016399 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,054,581 F3 · price: Sale prices reported for the transactions reported here range from $106.34 to $107.34. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 07, 2014 Filed Nov 12, 2014 17:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 146,895 | $8.01 | $1,175,894.48 |
DisclosureSEC source: 0001179110-14-016399 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2014 Filed Oct 9, 2014 18:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 146,895 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001179110-14-015300 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,718 Underlying: Common Stock · 146,895 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| October 07, 2014 Filed Oct 9, 2014 18:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 98,408 | $104.86 | $10,318,570.84 |
DisclosureSEC source: 0001179110-14-015300 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,048 F5 · price: Sale prices reported for the transactions reported here range from $104.52 to $105.30. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 07, 2014 Filed Oct 9, 2014 18:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 44,387 | $104.18 | $4,624,282.05 |
DisclosureSEC source: 0001179110-14-015300 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,072,456 F4 · price: Sale prices reported for the transactions reported here range from $103.59 to $104.51. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 07, 2014 Filed Oct 9, 2014 18:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,100 | $103.16 | $422,965.43 |
DisclosureSEC source: 0001179110-14-015300 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116,843 F3 · price: Sale prices reported for the transactions reported here range from $102.565 to $103.51. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 07, 2014 Filed Oct 9, 2014 18:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 146,895 | $8.01 | $1,175,894.48 |
DisclosureSEC source: 0001179110-14-015300 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2014 Filed Sep 10, 2014 20:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 146,895 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001179110-14-014045 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,613 Underlying: Common Stock · 146,895 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 08, 2014 Filed Sep 10, 2014 20:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 84,506 | $106.23 | $8,976,793.51 |
DisclosureSEC source: 0001179110-14-014045 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,048 F4 · price: Sale prices reported for the transactions reported here range from $105.97 to $106.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 08, 2014 Filed Sep 10, 2014 20:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 62,389 | $105.67 | $6,592,870.23 |
DisclosureSEC source: 0001179110-14-014045 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,554 F3 · price: Sale prices reported for the transactions reported here range from $104.96 to $105.96. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 08, 2014 Filed Sep 10, 2014 20:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 146,895 | $8.01 | $1,175,894.48 |
DisclosureSEC source: 0001179110-14-014045 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2014 Filed May 19, 2014 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 64,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008758 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,048 F1 · price: Charitable gift of shares. Read SEC document |
| May 08, 2014 Filed May 9, 2014 22:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001179110-14-008124 · edgar.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,508 Underlying: Common Stock · 100,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 08, 2014 Filed May 9, 2014 22:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $8.01 | $800,500.00 |
DisclosureSEC source: 0001179110-14-008124 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 82,968 | $79.92 | $6,630,802.56 |
DisclosureSEC source: 0001179110-14-004888 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,048 Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 159,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-004888 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,016 F2 · shares: Vesting of performance share awards on March 6, 2014 Read SEC document |
| February 14, 2014 Filed Mar 10, 2014 20:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 968 | $21.94 | $21,242.66 |
DisclosureSEC source: 0001179110-14-004888 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 862,016 F1 · shares: Amount of securities beneficially owned acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on February 14, 2014. Read SEC document |
| February 01, 2014 Filed Feb 5, 2014 01:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 64,910 | $0.00 Strike: $80.65 | $0.00 |
DisclosureSEC source: 0001179110-14-001950 · edgar.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,910 Underlying: Common Stock · 64,910 shares Expires 2024-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 23, 2014 Filed Jan 27, 2014 23:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 16,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001417 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,126 F2 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on February 1, 2013. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2015. Read SEC document |
| January 23, 2014 Filed Jan 27, 2014 23:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 34,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001417 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,694 F1 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on January 26, 2012. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2014. Read SEC document |
| November 25, 2013 Filed Nov 26, 2013 23:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy · Derivative | 12,492 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001179110-13-017105 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,492 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 25, 2013 Filed Nov 26, 2013 23:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 13,096 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-017105 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,096 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 25, 2013 Filed Nov 26, 2013 23:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 12,492 | $8.01 | $99,998.46 |
DisclosureSEC source: 0001179110-13-017105 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2013 Filed Nov 26, 2013 23:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 13,096 | $7.63 | $99,955.22 |
DisclosureSEC source: 0001179110-13-017105 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2013 Filed Nov 25, 2013 18:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 395,634 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-016995 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 395,634 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.